Thomas Szucs

Thomas Szucs is Director of The Institute of Pharmaceutical Medicine (European Center of Pharmaceutical Medicine) at the University of Basel, and, since 2010, the Chairman for Curriculum Matters for the Master Program in Public Health of the Universities of Basel, Bern and Zurich.

Prof. Szucs is President of the Board of the Helsana Group and BB Biotech AG and serves on the Boards of Biovertis AG ant the Kantonsspital Uri. He also serves as Vice President of the Outcomes Research Network of the Swiss Working Group of Clinical Cancer Research (SAKK).

Furthermore, Thomas Szucs is also a Professor and part-time lecturer for Medical Economics at the University of Zurich and honorary Professor at the University of Beijing.

Previously he was Chief Medical Officer of Hirslanden Holding, the largest private hospital chain in Switzerland. From 1998 to 2001 he was head of the Department of Medical Economics, a joint venture of the University Hospital in Zurich and the Institute of Social and Preventive Medicine of the University of Zurich.

Professor Szucs’ former appointments include head of research and founder of the Center of Pharmacoeconomics of the University of Milan, head of the working group for Clinical Economics at the University of Munich, senior consultant at Arthur D. Little Inc. and head of the Department of Health Economics at F. Hoffmann-La Roche Ltd. in Basel.

He holds a medical degree from the University of Basel, a Masters in Business Administration from the University of St. Gallen, Switzerland, a Master of Public Health degree from Harvard University, and is board certified in Pharmaceutical Medicine as well as in Prevention and Public Health. Recently, he has received a LL.M in International Business Law with a specialisation in Information- and Technology Law from the University of Zurich. He is also member of the editorial board of several scientific journals and has published more than 300 articles, book chapters and monographies. He has worked extensively in the field of pharmaceutical economics and epidemiology. In addition he is head of the Swiss Association of Health Economics.